Source:資料來源： India’s Choice by NYTimes印度的選擇nytimes


For an AIDS patient in a poor country lucky enough to get antiretroviral treatment, chances are that the pills that stave off death come from India.為艾滋病患者在一個貧窮的國家有幸獲得抗逆轉錄病毒治療，機會是藥丸即避開死亡來自印度。 Generic knockoffs of AIDS drugs made by Indian manufacturers - now treating patients in 200 countries - have brought the price of antiretroviral therapy down to $140 a year from $12,000.通用knockoffs艾滋病藥物所作出的印度製造商-現在治療的病人在2 00個國家-帶來了價格的抗逆轉錄病毒療法下降到1 4 0元，一年從一萬二千美元。

That luck may soon run out.這運氣，可能不久就會一發不可收拾。 India has become the world’s supplier of cheap AIDS drugs because it has the necessary raw materials and a thriving and sophisticated copycat drug industry made possible by laws that grant patents to the process of making medicines, rather than to the drugs themselves.印度已成為世界上的供應商的廉價艾滋病藥物，因為它所需的原料和繁榮的和複雜的模仿毒品業的可能，法律授予專利的過程中作出的藥品，而不是藥物本身。 But when India signed the World Trade Organization’s agreement on intellectual property in 1994, it was required to institute patents on products by Jan. 1, 2005.但是，當印度簽署了世界貿易組織的協議，關於知識產權在1994年，它必須學會專利的產品由2005年1月1日。 These rules have little to do with free trade and more to do with the lobbying power of the American and European pharmaceutical industries.這些規則有沒有什麼與自由貿易和更多的事情要做與遊說的權力，美國和歐洲製藥行業。

India’s government has issued rules that will effectively end the copycat industry for newer drugs.印度政府已發出的規則，將有效地結束抄襲業較新的藥物。 For the world’s poor, this will be a double hit - cutting off the supply of affordable medicines and removing the generic competition that drives down the cost of brand-name drugs.為世界上的窮人，這將是一個雙重打擊-切斷供應的可負擔得起的藥品和消除一般競爭驅動器的成本才得以降低的名牌藥品。

Who are these laws benefitting really?誰是這些法律惠及真的嗎？
Please let your voice be heard.請告訴您的聲音被聽到。